Global Colorectal Cancer Molecular Diagnostics Market Trends: Regional Breakdowns and Strategic Insights
Discover trends, market shifts, and competitive outlooks for the colorectal cancer molecular diagnostics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Fast Is The Colorectal Cancer Molecular Diagnostics Market Expected to Grow Between 2025 And 2029?
In recent times, the colorectal cancer molecular diagnostics market has exhibited significant growth. Projected expansion from $2.56 billion in 2024 to $2.77 billion in 2025, indicates a compound annual growth rate (CAGR) of 8.1%. The notable increase during the historical period is a result of the rising incidence of colorectal cancer, heightened awareness and screening initiatives, a growing focus on personalized medicine, and government efforts aimed at cancer control.
There is an anticipation of robust growth in the colorectal cancer molecular diagnostics market in the upcoming years. The market is projected to escalate to a value of $3.79 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. This estimated growth during the forecast period can be associated with factors such as an aging population and heightened risk factors, incorporation of genomic data into clinical proceedings, the surge in precision medicine methodologies, and worldwide cooperation in cancer research. Foreseeable trends during this period include a growing emphasis on early detection biomarkers, the integration of artificial intelligence (AI) into data interpretation, the rise in circulating tumor DNA (CTDNA) analysis, broadening of companion diagnostics for targeted therapies, and the concentration on immunotherapy biomarkers.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Colorectal Cancer Molecular Diagnostics Market?
The escalation in inflammatory bowel diseases (IBD) prevalence is anticipated to catalyze the expansion of the colorectal cancer molecular diagnostic market. IBD, chronic gastrointestinal disorders marked by inflammation in the digestive system, primarily affects the colon and rectum. Symptoms include abdominal discomfort, diarrhea, and weight reduction, which are dealt with through medications, lifestyle modifications, and sometimes surgery. Elevated cases of IBD increase the need for precise, effective, and advanced diagnostic systems, as colorectal cancer (CRC) systemic therapy’s decision largely hinge on the tumor’s molecular evaluation outcome. For instance, research conducted by Crohn’s & Colitis UK in April 2024 identified that 500,000 UK residents live with IBD, almost twice the previous estimates. Thus, the rising number of IBD cases will stimulate the colorectal cancer molecular diagnostic market’s growth. The escalating cases of colorectal cancer are predicted to fuel the growth of the colorectal cancer molecular diagnostics market. It’s a disease affecting the colon or rectum, parts of the digestive system, formed when cells in these areas uncontrollably multiply to form a tumor. An uptick in colorectal cancer boosts demand for molecular diagnostics to detect and treat cancer. As per the American Cancer Society, a leading voluntary health organization in the US with a goal to eradicate cancer, roughly 153,020 individuals are expected to be diagnosed with CRC (colorectal cancer) in March 2023. Out of this, approximately 52,550 are projected to lose their life to the disease, with 19,550 cases and 3,750 deaths affecting individuals under 50. Therefore, the surging colorectal cancer cases are propelling the colorectal cancer molecular diagnostics market’s growth.
Which Key Market Segments Comprise the Colorectal Cancer Molecular Diagnostics Market and Drive Its Revenue Growth?
The colorectal cancer molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings
Subsegments:
1) By Instruments: PCR Machines, Sequencers, Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs
3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp
Which Areas Are Leading Regions in the Colorectal Cancer Molecular Diagnostics Market Expansion Across the Globe?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Strategic Trends Steering theColorectal Cancer Molecular Diagnostics Market Direction?
Leading corporations within the colorectal cancer molecular diagnostic market are at the forefront of creating exceptional molecular diagnostics and customized medical treatments, like the shield blood test technique to discover colorectal cancer in its manageable, early stages. The Shield Blood Test is a preliminary blood examination tailored to recognize early-stage colorectal cancer (CRC). In May 2022, for example, the Shield Blood Test was initiated by Guardant Health, a biotechnology organization from the US specializing in molecular diagnostic products for cancer. The accessible shield exam provides a user-friendly screening choice that merely requires a straightforward blood draw to alleviate trials associated with patient enthusiasm for screening. The test displayed a 91% sensitivity rate for identifying colorectal cancer and a 20% rate for advanced adenomas, while achieving a specificity of 92%. By making use of data from a diverse array of more than 2,000 colorectal cancer sufferers, 357 with advanced adenoma, and 3,757 healthy individuals, the Shield test is able to identify early indications of colorectal cancer in the blood.
View the full report here:
How Is the Colorectal Cancer Molecular Diagnostics Market Conceptually Defined?
Colorectal cancer, also known as colon cancer or rectal cancer, is a malignant tumor that develops in the colon (the large intestine) or the rectum (the final portion of the digestive tract just before the anus). It is a type of cancer that arises from the inner lining of these parts of the gastrointestinal system. Colorectal cancer molecular diagnostics uses advanced techniques to identify specific genetic mutations, alterations, and biomarkers that play a role in the development, progression, and treatment response of colorectal cancer.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
